US Stock MarketDetailed Quotes
GNMSF GENMAB AS
- 226.000
- +5.280+2.39%
15min DelayClose Nov 4 15:31 ET
14.35BMarket Cap18.43P/E (TTM)
229.340High218.700Low2.98KVolume229.340Open220.720Pre Close673.22KTurnover0.01%Turnover Ratio23.57P/E (Static)63.51MShares334.32852wk High3.18P/B14.20BFloat Cap211.82452wk Low--Dividend TTM62.85MShs Float500.920Historical High--Div YieldTTM4.82%Amplitude211.824Historical Low225.987Avg Price1Lot Size
About GENMAB AS Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGNMSF
Company NameGENMAB AS
Listing DateJul 18, 2019
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketPink Market
Employees2204
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 44.30M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 19.60M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 10.10M
- Dr. Judith Klimovsky
- Executive Vice President and Chief Development Officer
- 21.70M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 13.20M
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 21.80M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 19.80M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 8.90M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.10M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.10M
- Deirdre P. Connelly
- Chairman of the Board
- 2.80M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 800.00K
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 800.00K
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 1.70M
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 1.50M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.50M
- Elizabeth G. O’Farrell
- Independent Director
- 1.90M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data